Novartis, Sandoz family

Sandoz family foundation offers USD 3 billion worth of Novartis shares
Emasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares in Novartis, aiming to raise up to $3 billion through an
Sandoz family to get $2.9 billion from offloading part of its Novartis stake
The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal said on Wednesday. Emasan AG sold 26.
Sandoz Family’s Emasan AG Sells Novartis Stake for $2.9 Billion in Major Cash-Out
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion). The sale, conducted through
Sandoz Family Pares Novartis Stake With $2.9 Billion Sale
Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion).
Novartis Stock: Sandoz Family Reduces Significant Stake
The investment company of the Sandoz family, Emasan AG, has divested a substantial portion of its holdings in Swiss pharmaceutical giant Novartis. Through an accelerated bookbuilding process, 26.5 million shares were sold at 98.
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuilt offering,
Sandoz Family to Sell $2.9 Billion Stake in Novartis
(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.
GlobalCapital16h
Block of €3.4bn in Ferrari tops €2.8bn Novartis trade
The Ferrari deal is expected to be the largest of a clutch of block trades this week, including a Sfr2.6bn (€2.8bn) block in ...
pharmaphorum2y
Sandoz bulks up ahead of possible sale with Coalesce buy
Analysts have suggested its financial troubles could make a sale more difficult, as could untangling Sandoz from Novartis' broader manufacturing operations, although the launch of new biosimilars ...